Skip to main content

Omnicell Value Stock - Dividend - Research Selection

Omnicell

ISIN: US68213N1090, WKN: 632313

Market price date: 24.05.2021
Market price: 137,05 USD




Omnicell Fundamental data and company key figures of the share

Annual reports in USD
Key figures 13-02-2021
Cash flow
Net operating cash flow 185.870.000
Capital Expenditures -54.866.000
Free cash flow 131.004.000
Balance sheet
Total Equity 967.503.000
Liabilities & Shareholders equity 1.824.500.000
Income statement
Net income 32.194.000
Eps (diluted) 0,740
Diluted shares outstanding 43.743.000
Net sales/revenue 892.208.000

Fundamental ratios calculated on: 24-05-2021

Ratios
Key figures 24-05-2021
Cash flow
P/C 32,25
   
P/FC 45,76
Balance sheet
ROI1,77
ROE53,03
Income statement
P/E185,20
Div. Yield0,00%
P/B6,20
P/S6,72


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolOMCL
Market Capitalization5.994.978.304,00 USD
Country
IndicesNASDAQ Comp.
Sectors
Raw Data SourceUS GAAP in Millionen USD
Stock Split
Internetwww.omnicell.com


Description of the company

Omnicell, Inc. (Omnicell) is a provider of automated solutions for hospital medication and supply management. The Company´s automation and analytics solutions are designed to enable healthcare facilities to acquire, manage, dispense and administer medications and medical-surgical supplies. Its systems provide medication control and dispensing solution starting from the point of entry into the hospital and other health care providers, through the central pharmacy, to the nursing station and to the patient´s bedside. Omincell´s medication-use product line includes its OmniRx, SinglePointe, AnywhereRN, Anesthesia Workstation, WorkflowRx, Controlled Substance Management, OmniLinkRx, Savvy Mobile Medication System, and Pandora Data Analytics products. In May 2012, the Company acquired MTS Medication Technologies, Inc.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.omnicell.com